Latest Cash Flow News

BCAL Diagnostics has reported strong early commercial uptake of its BREASTEST plus non-invasive breast cancer diagnostic test, alongside a new partnership with Cancer Care Associates to expand market reach.

Emerald Resources NL reported steady gold output at its Okvau Mine while unveiling significant resource expansions at its Dingo Range and Memot projects, alongside clearing its debt.

Tlou Energy Limited’s latest quarterly cash flow report reveals a cautious financial position with A$2.74 million in available funding, supporting approximately 2.5 quarters of operations as exploration activities continue.

LCL Resources has secured a A$14 million cash deal plus royalty rights by divesting its Colombian projects to Tiger Gold Corporation, while advancing promising exploration programs in Papua New Guinea.

Noxopharm has initiated its HERACLES clinical trial for SOF-SKN, marking a key milestone for its Sofra platform, while deepening partnerships and actively seeking new funding to sustain development.

Opthea has discontinued its sozinibercept program after Phase 3 trial failures, leading to drastic staff cuts and a sharp decline in cash reserves amid ongoing funding negotiations.

DroneShield Limited has reported a record-breaking second quarter with revenues surging 480% year-on-year, underpinned by a robust $176 million in committed sales and a $2.3 billion pipeline. The company is aggressively expanding manufacturing and investing in next-generation counter-drone technologies to meet soaring global demand.

IGO Limited reported a robust operational quarter with improved safety and solid production at Greenbushes and Nova, offset by challenges at its Kwinana lithium refinery and an expected asset impairment.

IGO Limited reported robust operational performance in Q4 FY25 with improved safety and higher production at Greenbushes and Nova, while facing significant impairment at its Kwinana lithium refinery.

Sarytogan Graphite Limited reports softer ore than expected, improved graphite concentrate grades above 90%, and gains European Union strategic project status, advancing its Definitive Feasibility Study on track for mid-2026 completion.

Immutep Limited advances its pivotal Phase III lung cancer trial and reports promising results across multiple oncology and autoimmune programs, supported by a solid cash position to fund operations through 2026.

West African Resources Limited reported a robust quarter with strong operating cash inflows and significant investment in exploration, ending June 2025 with A$279 million in cash. The company’s strategic financing and spending patterns highlight its commitment to growth in West Africa’s gold sector.